before pain signals reach the brain," according to the FDA. It will use Journavx as its brand name. Vertex CEO Reshma Kewalramani touted Journavx as the "first new class of pain medicine approved ...

The drug, which was developed by Vertex Pharmaceuticals in Boston and tested as a pain treatment following surgeries, targets the nerves near an injury site instead of in the brain. “It works in a way ...